Compare Abeona Therapeutics Inc (ABEO) vs J M Smucker Co (SJM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs J M Smucker Co — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while J M Smucker Co trades at $112.92 (market cap $12.10B). The key difference: J M Smucker Co is far larger — about 32.4× Abeona Therapeutics Inc's market cap, and J M Smucker Co pays a 3.89% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SJM | |
|---|---|---|
Market Cap | $373.32M | $12.10B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $117.05 |
52-Week Low | $4.17 | $89.53 |
Enterprise Value | $228.22M | $19.13B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
J.M. Smucker (SJM) trades at $113.24, down 2.61% on the day, with a bullish technical signal from moving averages. The company reported mixed Q4 2026 results, beating EPS estimates but facing sales pressure, with fiscal 2027 revenue guidance projecting a 3-4% decline. Strong cash flow supports a sustainable 4% dividend yield, while valuation metrics show a P/E of 22.05 and P/S of 1.32.
SJM presents a value opportunity with analyst consensus at $122.92 (8.5% upside), but faces headwinds from weak sales visibility and portfolio challenges. The stock's outlook hinges on Uncrustables growth and coffee margin recovery, with balanced risks between dividend stability and competitive pressures in packaged foods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
